CFTR Gene clinical trials
25 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- A Study Assessing KB407 for the Treatment of Cystic Fibrosis
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
- Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
- Personalized Theratyping Trial
- A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
- Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
- BEGIN Novel ImagiNG Biomarkers
- The Cancer of the Pancreas Screening-5 CAPS5)Study
- Rare CFTR Mutation Cell Collection Protocol (RARE)
- Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
- Genetic Risk Factor for Heat Stroke
- Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
- Regional Phenotyping of CF and Non-CF Bronchiectasis
- Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
- Sinus Disease in Young Children With Cystic Fibrosis
- The Effects of the CF Carrier State on the Kidneys and Pancreas
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
- Role of Genetic Factors in the Development of Lung Disease
- Exercise in Child Health
- Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
- A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
- Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
- A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “CFTR Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.